Abstract:Importance: The COVID-19 pandemic led to the use of lung transplant as a lifesaving therapy for patients with irreversible lung injury. Limited information is currently available regarding the outcomes associated with this treatment modality. Objective: To describe the outcomes following lung transplant for COVID-19-related acute respiratory distress syndrome or pulmonary fibrosis. Design, setting, and participants: In this cohort study, lung transplant recipient and donor characteristics and outcomes following lung transplant for COVID-19-related acute respiratory distress syndrome or pulmonary fibrosis were extracted from the US United Network for Organ Sharing database from March 2020 to August 2022 with a median (IQR) follow-up period of 186 (64-359) days in the acute respiratory distress syndrome group and 181 (40-350) days in the pulmonary fibrosis group. Overall survival was calculated using the Kaplan-Meier method. Cox proportional regression models were used to examine the association of certain variables with overall survival. Exposures: Lung transplant following COVID-19-related acute respiratory distress syndrome or pulmonary fibrosis. Main outcomes and measures: Overall survival and graft failure rates. Results: Among 385 included patients undergoing lung transplant, 195 had COVID-19-related acute respiratory distress syndrome (142 male [72.8%]; median [IQR] age, 46 [38-54] years; median [IQR] allocation score, 88.3 [80.5-91.1]) and 190 had COVID-19-related pulmonary fibrosis (150 male [78.9%]; median [IQR] age, 54 [45-62]; median [IQR] allocation score, 78.5 [47.7-88.3]). There were 16 instances of acute rejection (8.7%) in the acute respiratory distress syndrome group and 15 (8.6%) in the pulmonary fibrosis group. The 1-, 6-, and 12- month overall survival rates were 0.99 (95% CI, 0.96-0.99), 0.95 (95% CI, 0.91-0.98), and 0.88 (95% CI, 0.80-0.94) for the acute respiratory distress syndrome cohort and 0.96 (95% CI, 0.92-0.98), 0.92 (95% CI, 0.86-0.96), and 0.84 (95% CI, 0.74-0.90) for the pulmonary fibrosis cohort. Freedom from graft failure rates were 0.98 (95% CI, 0.96-0.99), 0.95 (95% CI, 0.90-0.97), and 0.88 (95% CI, 0.79-0.93) in the 1-, 6-, and 12-month follow-up periods in the acute respiratory distress cohort and 0.96 (95% CI, 0.92-0.98), 0.93 (95% CI, 0.87-0.96), and 0.85 (95% CI, 0.74-0.91) in the pulmonary fibrosis cohort, respectively. Receiving a graft from a donor with a heavy and prolonged history of smoking was associated with worse overall survival in the acute respiratory distress syndrome cohort, whereas the characteristics associated with worse overall survival in the pulmonary fibrosis cohort included female recipient, male donor, and high recipient body mass index. Conclusions and relevance: In this study, outcomes following lung transplant were similar in patients with irreversible respiratory failure due to COVID-19 and those with other pretransplant etiologies.

A Multi‐Center International Analysis of Lung Transplantation Outcomes in Patients With COVID‐19

LUNG TRANSPLANTATION DURING THE OUTBREAK OF CORONAVIRUS DISEASE 2019: EARLY EXPERIENCE FROM CHINA

Lung transplantation during the outbreak of Coronavirus Disease 2019 in China

Lung Transplantation in the United States for COVID-19 Related Lung Disease During the Pandemic

A Single-center Experience With >200 Lung Transplant Recipients With COVID-19 Infection

Outcomes Following Lung Transplant for COVID-19-Related Complications in the US

Clinical characteristics and outcomes of lung transplantation in patients with severe COVID-19 infection: A systematic review and meta-analysis

Lung Transplant Recipients and COVID-19: Report of Two Cases

First lung and kidney multi-organ transplant following COVID-19 Infection

The impact of high volumes of COVID‐related lung transplant on waitlist mortality for non‐COVID candidates in the United States

Clinical characteristics and epidemiology survey of lung transplantation recipients accepting surgeries during COVID 19 pandemic:from area near Hubei Province (Preprint)

Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study

Clinical characteristics and epidemiology survey of lung transplantation recipients accepting surgeries during the COVID-19 pandemic:from area near Hubei Province

Lung transplantation in patients with lung disease secondary to coronavirus disease 2019 infection

LUNG TRANSPLANTATION FOR AN ARDS PATIENT POST-COVID-19 INFECTION

Treatment of Patients After Lung Transplantation With Covid Infection During Long-Term Follow-Up

SARS-CoV-2 and lung transplantation. What do we know?

Early Experience With COVID-19 and Solid Organ Transplantation at a US High-volume Transplant Center

Early Outcomes of COVID-19 Lung Transplantation Recipients in Korea: A Single-Center Study

Lung Transplantation As Therapeutic Option in Acute Respiratory Distress Syndrome for Coronavirus Disease 2019-Related Pulmonary Fibrosis.

A comparison of outcomes after lung transplantation between European and North American centers